Recent Media Coverage

The national pharmaceutical panel is scheduled to make its recommendation on Thursday, but the government will wait for a third panel, which has not said when it will reach its conclusion, before deciding whether to grant approval.

This new partnership between the health regulatory authorities of the EU and Brazil is an important step towards mutual recognition and regulatory harmonisation to improve human and animal health.

The agreements will bolster India's arsenal of drugs to battle its catastrophic second wave of the pandemic, which has led to an acute shortage of coronavirus medicines including remdesivir and tocilizumab.

Sinopharm received emergency use listing from the World Health Organization (WHO) last Friday, making it eligible for the COVAX programme and bolstering Beijing's push for a bigger role in inoculating the world.

That was up from 1.4 billion doses announced in March.

The potential cost-effectiveness estimates are significantly higher than what NICE considers to be an appropriate use of NHS resources.

Controversial move to waive patent protections for vaccines is a key element.

Concerns have risen on potential side-effects of the Anglo-Swedish COVID-19 vaccine.

Western pharmaceutical companies, many of which have received government support to develop vaccines, strongly oppose the transfer of intellectual property to make them.

The solution is to ease restrictions on exporting shots and build more production capacity.

The new system in New Zealand will be up and running within two years.

Democrats have no workable plan to tackle the cost of prescription drugs, even with full control of Washington and after campaigning on the issue for years.